BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28161464)

  • 1. Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model.
    Rao M; Cadieux N; Fitzpatrick M; Reed S; Arsenian S; Valentini D; Parida S; Dodoo E; Zumla A; Maeurer M
    Int J Infect Dis; 2017 Mar; 56():274-282. PubMed ID: 28161464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ
    PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
    Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
    Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
    Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
    Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
    Kim A; Hur YG; Gu S; Cho SN
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.
    Dou J; Wang Y; Yu F; Yang H; Wang J; He X; Xu W; Chen J; Hu K
    Int J Immunogenet; 2012 Apr; 39(2):183-90. PubMed ID: 22152009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization With
    Diogo GR; Hart P; Copland A; Kim MY; Tran AC; Poerio N; Singh M; Paul MJ; Fraziano M; Reljic R
    Front Immunol; 2019; 10():1349. PubMed ID: 31293568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.
    Singh S; Saraav I; Sharma S
    Vaccine; 2014 Feb; 32(6):712-6. PubMed ID: 24300592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
    Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
    Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHO expressed recombinant human lactoferrin as an adjuvant for BCG.
    Hwang SA; Kruzel ML; Actor JK
    Int J Immunopathol Pharmacol; 2015 Dec; 28(4):452-68. PubMed ID: 26315722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule.
    Luo Y; Jiang W; Da Z; Wang B; Hu L; Zhang Y; An R; Yu H; Sun H; Tang K; Tang Z; Wang Y; Jing T; Zhu B
    Scand J Immunol; 2012 Mar; 75(3):293-300. PubMed ID: 22117839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.
    Siddiqui KF; Amir M; Khan N; Rama Krishna G; Sheikh JA; Rajagopal K; Agrewala JN
    Clin Exp Immunol; 2015 Aug; 181(2):286-96. PubMed ID: 25845290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
    Brandt L; Skeiky YA; Alderson MR; Lobet Y; Dalemans W; Turner OC; Basaraba RJ; Izzo AA; Lasco TM; Chapman PL; Reed SG; Orme IM
    Infect Immun; 2004 Nov; 72(11):6622-32. PubMed ID: 15501795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
    Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
    PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
    Orr MT; Beebe EA; Hudson TE; Argilla D; Huang PW; Reese VA; Fox CB; Reed SG; Coler RN
    Vaccine; 2015 Nov; 33(48):6570-8. PubMed ID: 26541135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.